United States Patent 9,402,805: Claim Scope, Exclusivity, and Ciprofloxacin-Dexamethasone Patent Landscape

U.S. Patent No. 9,402,805 protects a narrowly defined method of treating ear infections with a ciprofloxacin-dexamethasone aqueous suspension. The independent claim requires a diagnosed patient with otitis media and an open tympanic membrane, or acute otitis externa, together with a specific formulation, dose volume, and twice-daily administration schedule. The patent does not broadly claim every ciprofloxacin-dexamethasone otic product.

The commercially relevant embodiment tracks the composition and dosing of Ciprodex, an otic suspension containing 0.3% ciprofloxacin and 0.1% dexamethasone. The strongest claim is claim 12, which recites the principal formulation in near-product-specific detail. The patent’s commercial significance depends on whether a competing product’s label directs treatment through an open tympanic membrane, uses the claimed formulation parameters, and adopts the claimed three- or four-drop, twice-daily regimen.

What does U.S. Patent 9,402,805 cover?

Patent 9,402,805 covers a method of treating specified ear infections by applying a ciprofloxacin-dexamethasone suspension into the ear canal.

The independent claim has four principal limitations:

The patient must be diagnosed with otitis media and an open tympanic membrane, or acute otitis externa.
The formulation must contain ciprofloxacin, dexamethasone, a tonicity agent, a nonionic surfactant, and a buffer.
The formulation must fall within specified concentration ranges.
The product must be administered as three or four drops, twice daily, with each drop measuring 30-35 microliters.

The claim therefore combines:

A patient-selection limitation.
A disease and anatomical-condition limitation.
A formulation limitation.
A dose-volume limitation.
A dosing-frequency limitation.

This combination makes the patent materially narrower than a patent claiming the active ingredients or formulation alone.

What formulation ranges are required by claim 1?

Claim 1 requires the following ranges:

Component	Claimed range
Dexamethasone	0.01%-0.5% by weight
Ciprofloxacin	0.1%-0.4% by weight
Tonicity agent	0.1%-0.9% by weight
Nonionic surfactant	0.01%-0.2% by weight
Buffer	Required, with no numerical concentration specified
Drop size	30-35 microliters
Administration	Three or four drops, twice daily

A product outside one of these limitations may avoid literal infringement of claim 1. For example, a formulation with the same active ingredients but no nonionic surfactant, a different drop volume, or a dosing schedule other than twice daily would not meet every express limitation of the independent claim.

The doctrine of equivalents could affect an infringement analysis, but prosecution history, claim construction, and the technical significance of the numerical ranges would be material. Numerical concentration and drop-volume limitations often create meaningful design-around opportunities.

How do claims 2 through 11 narrow the patent?

Claims 2 through 11 add formulation and excipient limitations. They create fallback positions but reduce the number of potentially covered products.

Claim	Additional limitation
2	Dexamethasone alcohol and ciprofloxacin hydrochloride monohydrate
3	0.1% dexamethasone and 0.3% ciprofloxacin
4	Dexamethasone mean-volume particle size below 3 micrometers
5	Sodium chloride as the tonicity agent
6	Osmolality of 250-350 mOsm
7	Tyloxapol as the nonionic surfactant
8	Tyloxapol at 0.05%
9	A suspending agent
10	Hydroxyethylcellulose as the suspending agent
11	Hydroxyethylcellulose at 0.2%

Claims 3, 7, 8, 10, and 11 are especially relevant to a Ciprodex-like formulation. Claims 2, 5, 6, and 10 collectively describe a conventional commercial suspension architecture: ciprofloxacin hydrochloride monohydrate, dexamethasone alcohol, sodium chloride, tyloxapol, and hydroxyethylcellulose.

Claim 4 adds a physical-property limitation that may require particle-size testing or access to manufacturing specifications. A competitor could potentially use the same active ingredients and nominal concentrations while selecting a different corticosteroid particle-size distribution.

What is the scope of claim 12?

Claim 12 is the most formulation-specific claim. It requires a suspension that consists essentially of:

0.1% dexamethasone alcohol;
0.35% ciprofloxacin hydrochloride monohydrate;
Sodium chloride sufficient to produce 250-350 mOsm osmolality;
0.2% hydroxyethylcellulose;
0.05% tyloxapol;
Sodium acetate and acetic acid buffer;
0.01% benzalkonium chloride;
0.01% edetate disodium;
0.6% boric acid; and
A pH of approximately 4.5.

The phrase “consists essentially of” generally permits components that do not materially affect the basic and novel characteristics of the claimed composition. It is narrower than “comprising” and broader than “consisting of.” The infringement analysis would therefore turn on whether an added ingredient materially changes the suspension’s relevant characteristics.

Claim 12 is vulnerable to product-specific design-around strategies. Potential variables include:

Changing the corticosteroid concentration.
Replacing tyloxapol with another surfactant.
Replacing hydroxyethylcellulose with another suspending agent.
Altering the buffer system.
Moving the pH outside the “about 4.5” range.
Using a different preservative or chelating agent.
Changing the ciprofloxacin concentration from 0.35%.

A design-around would need to account for claims 1-11 and 13-22, not only claim 12.

What do claims 13 through 22 protect?

Claims 13 through 22 focus on treatment context, patient population, labeling, and administration details.

Claims 13 and 19-21: middle-ear delivery and clinical outcomes

Claim 13 requires pumping the tragus to force the suspension through the open tympanic membrane into the middle ear. This limitation is directed to practical delivery in patients with a perforated tympanic membrane or tympanostomy tube.

Claims 19-21 cover treatment of:

Otorrhea associated with a middle-ear infection.
Acute otitis externa associated with a middle-ear infection.
Granulation tissue associated with a middle-ear infection.

These claims may be important in assessing a generic label. A label that expressly directs use for otorrhea, granulation tissue, or infection involving the middle ear may create additional method-of-use exposure.

Claims 14-16: disease and patient subgroups

Claim 14 limits otitis media to acute otitis media. Claim 15 covers chronic suppurative otitis media. Claim 16 limits the patient to a pediatric patient.

Ciprodex is primarily associated with pediatric acute otitis media in patients with tympanostomy tubes and acute otitis externa. The pediatric limitation in claim 16 is therefore commercially significant even though it narrows the claim.

Claim 17: packaged directions for use

Claim 17 covers the composition when packaged with directions stating that it may treat otitis media in patients with an open tympanic membrane.

This claim is directed to labeling and packaging conduct. A generic applicant’s proposed labeling is therefore central to risk assessment. Under the Hatch-Waxman framework, a Paragraph IV certification or a proposed label that retains a patented indication can create litigation exposure. A section viii statement or “skinny label” may reduce risk if the patented use can be omitted without encouraging the patented method.

Claim 18: pH

Claim 18 requires a pH of 3-6. This is a broad dependent limitation relative to claim 12’s approximate pH of 4.5. Products with an acidic pH within this range may remain exposed even if they do not match the precise claim 12 formulation.

Claim 22: four drops twice daily

Claim 22 narrows claim 1 to four drops administered twice daily. This limitation closely tracks the labeled Ciprodex regimen for specified otic indications. It may be easier to prove from a product label than formulation parameters that are not publicly disclosed.

When does U.S. Patent 9,402,805 expire?

U.S. Patent 9,402,805 was issued on July 26, 2016. The patent is associated with an Alcon ciprofloxacin-dexamethasone otic patent family and has a nominal patent-term endpoint in late 2029 based on its priority and filing history. The operative expiration date must be taken from the USPTO patent record, including any patent-term adjustment or terminal disclaimer recorded for the specific patent. [1]

The patent term is separate from FDA regulatory exclusivity:

Exclusivity category	Relevance
Patent term	Controls enforceable patent rights, subject to validity and litigation outcomes
New-drug exclusivity	Applies to the NDA approval period and is separate from patent term
Pediatric exclusivity	Can add six months to qualifying listed patents and exclusivity
Orphan-drug exclusivity	Generally not the principal issue for ciprofloxacin-dexamethasone otic products
Regulatory data exclusivity	Does not automatically prevent all abbreviated applications after the applicable period

Ciprodex received FDA approval under NDA 021537. The original product is a prescription otic suspension containing ciprofloxacin and dexamethasone. [2] FDA approval does not establish that every patent covering the product remains valid or enforceable.

What is the Orange Book status of patent 9,402,805?

The FDA Orange Book is the principal source for determining whether a patent has been submitted for listing against an approved drug application. Patent listing is relevant to Hatch-Waxman certification obligations and the potential for a 30-month stay after a timely patent-infringement action. [3]

For Ciprodex and authorized generic competition, the relevant questions are:

Whether patent 9,402,805 is listed against NDA 021537.
Whether it is listed as a drug-substance, drug-product, or method-of-use patent.
Whether the listed use corresponds to the proposed generic label.
Whether the listing remains active in the current Orange Book edition.
Whether the applicant can make a section viii statement for the patented method.

Because patent 9,402,805 is directed to a method of treatment rather than a composition standing alone, any Orange Book listing would most directly affect labeling and method-of-use certifications. A listed method patent does not automatically block approval of every generic ciprofloxacin-dexamethasone otic product.

Which products compete with the patented Ciprodex method?

The competitive field includes branded Ciprodex, authorized generic supply, and generic ciprofloxacin-dexamethasone otic suspensions.

Product category	Active ingredients	Form	Main patent question
Ciprodex	Ciprofloxacin 0.3% and dexamethasone 0.1%	Otic suspension	Direct commercial reference point
Authorized generic	Same or materially equivalent product	Otic suspension	Exposure depends on supply and label
Generic combination suspension	Ciprofloxacin and dexamethasone	Otic suspension	Label, formulation, and dose-volume comparison
Ciprofloxacin-only otic products	Ciprofloxacin	Solution or suspension	Generally outside the combination limitation
Steroid-only otic products	Dexamethasone or another corticosteroid	Solution or suspension	Generally outside the ciprofloxacin limitation

The key distinction is between an identical or near-identical suspension and a product that uses the same active ingredients but a different vehicle. Patent 9,402,805 reaches beyond the active ingredients, but only when the formulation and clinical-use conditions are satisfied.

What Paragraph IV risks apply to generic applicants?

A generic applicant seeking approval for a ciprofloxacin-dexamethasone otic product could face several certification scenarios.

Paragraph IV certification

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. If the patent holder brings a timely infringement action, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court decisions. [4]

For this patent, an applicant could challenge:

The written description and enablement of the full concentration ranges.
Obviousness over earlier ciprofloxacin-dexamethasone otic formulations.
The novelty or obviousness of the dosing volume and frequency.
The patentability of the diagnostic and open-tympanic-membrane limitations.
The enforceability of a claim directed to a labeled use.
Whether the proposed product or label meets every limitation.

Section viii statement

A section viii statement may be available where the generic applicant omits a patented method of use from its labeling. The strategy is more viable when the patented indication can be removed without leaving instructions that encourage the patented method.

For claims 17 and 19-21, the exact proposed label language is decisive. A label that retains treatment through an open tympanic membrane or treatment of middle-ear otorrhea may present greater exposure than a label limited to acute otitis externa without middle-ear involvement.

How strong is the patent estate?

Patent 9,402,805 has moderate commercial strength and narrower blocking power.

Strengths

The claims track a clinically used product and regimen.
The independent claim combines formulation and use limitations.
Claims 3, 8, 11, 16, and 22 align with commercially recognizable product and dosing characteristics.
Claim 17 creates a direct label-based risk for a generic applicant.
The open-tympanic-membrane limitation addresses a clinically important use of otic formulations.

Weaknesses

The patent does not broadly claim ciprofloxacin-dexamethasone compositions.
Multiple numerical limitations create design-around opportunities.
The formulation elements may be vulnerable to obviousness arguments if disclosed in earlier otic suspension patents or regulatory materials.
Method claims depend on actual patient diagnosis, anatomy, treatment, and label instructions.
Claims directed to formulation characteristics may be difficult to prove without discovery of manufacturing and quality-control records.

The strongest enforcement scenario would involve a generic product with the same or substantially identical formulation, a label covering otitis media with an open tympanic membrane, and the four-drop twice-daily regimen.

What manufacturing and geographic barriers exist?

The patent is a United States right. It does not directly block manufacture, sale, or use outside the United States. Foreign patent family members must be assessed separately by jurisdiction.

Manufacturing-related risk is concentrated in the suspension process and quality attributes, including:

Dexamethasone particle-size distribution.
Uniform dispersion of ciprofloxacin and dexamethasone.
Control of pH and osmolality.
Surfactant and suspending-agent selection.
Preservative concentration.
Drop-volume delivery from the container.
Container-closure compatibility and dosing reproducibility.

A product may avoid a claim by changing its formulation, but FDA approval requires pharmaceutical equivalence, bioequivalence or applicable clinical support, stability, sterility or microbiological controls, and acceptable labeling. Regulatory design-around and patent design-around objectives can conflict.

What litigation and settlement issues affect this patent?

A complete litigation determination requires reviewing the USPTO assignment and maintenance records, the FDA Orange Book, ANDA litigation dockets, and any settlement filings. The principal litigation issues for this patent would be:

Whether a generic applicant made a Paragraph IV certification.
Whether the patent holder sued within the statutory period.
Whether a 30-month stay was triggered.
Whether the parties entered a license or launch settlement.
Whether an authorized generic agreement changed market-entry timing.
Whether the patent was invalidated, narrowed, disclaimed, or allowed to expire.

Patent 9,402,805 should not be analyzed in isolation. Earlier Ciprodex formulation patents, continuation patents, listed method-of-use patents, and regulatory exclusivity may have controlled entry at different times. A settlement involving one family member may not eliminate exposure under another patent unless the agreement expressly covers it.

Key Takeaways

Patent 9,402,805 is a method-of-treatment patent, not a broad composition patent.
Claim 1 requires a specific diagnosis, open tympanic membrane or acute otitis externa, formulation, drop size, and twice-daily regimen.
Claim 12 is the most product-specific claim and recites a Ciprodex-like formulation in detail.
Claims 17 and 22 create significant label and dosing exposure for generic applicants.
The patent’s nominal term extends into late 2029, subject to the USPTO-recorded expiration calculation.
A generic product may reduce risk through a section viii label carve-out, formulation changes, altered dosing instructions, or a Paragraph IV validity and non-infringement challenge.
The strongest infringement case would involve a near-identical formulation and a label expressly covering otitis media with an open tympanic membrane.
Orange Book listing, current litigation, settlements, and patent-term adjustment must be evaluated from the current FDA, USPTO, and court records before making an entry decision.

FAQs About U.S. Patent 9,402,805

Does patent 9,402,805 claim Ciprodex itself?

No. The patent claims methods of using a ciprofloxacin-dexamethasone suspension. Claim 12 closely describes a Ciprodex-like formulation, but the patent does not function as an unrestricted composition claim.

Can a generic ciprofloxacin-dexamethasone solution avoid patent 9,402,805?

Potentially. The claims require an aqueous suspension. A true solution would not satisfy that limitation, although other patents, regulatory requirements, or doctrine-of-equivalents arguments could remain relevant.

Does treating acute otitis externa infringe the patent?

It can, if the product and administration meet all limitations of claim 1 or a dependent claim. The claim expressly includes acute otitis externa, but the formulation, drop volume, dosing frequency, and other limitations still apply.

Is a pediatric-only generic automatically outside the patent?

No. Claim 16 expressly covers pediatric patients. A pediatric label may therefore increase, rather than eliminate, exposure if the remaining limitations are also met.

Does a different dropper bottle avoid infringement?

Not necessarily. A different container may alter the delivered drop volume, but the analysis depends on the actual drop size and whether the product is administered as three or four 30-35 microliter drops twice daily.

References

United States Patent and Trademark Office. (2016). U.S. Patent No. 9,402,805, methods of treating otic infections using ciprofloxacin and dexamethasone.
U.S. Food and Drug Administration. (2003). Ciprodex prescribing information, NDA 021537.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Code, 21 U.S.C. § 355(j). (2024). Abbreviated applications for new drugs.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1429780	⤷ Start Trial	CA 2012 00045	Denmark	⤷ Start Trial
European Patent Office	1429780	⤷ Start Trial	13C0012	France	⤷ Start Trial
European Patent Office	1429780	⤷ Start Trial	SPC/GB12/058	United Kingdom	⤷ Start Trial
European Patent Office	1429780	⤷ Start Trial	122012000070	Germany	⤷ Start Trial
European Patent Office	1429780	⤷ Start Trial	132013902137451	Italy	⤷ Start Trial
Austria	313328	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,402,805

Summary for Patent: 9,402,805